Vigonvita Life Sciences Co., Ltd. (HKG:2630)
Hong Kong · Delayed Price · Currency is HKD 81.20
-0.70 (-0.85%)
Sep 10, 2026, 4:08 PM HKT
Vigonvita Life Sciences Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Cash & Equivalents | 308.09 | 447.97 | 121.14 | 95.97 |
Short-Term Investments | - | 0.25 | 0.21 | 0.24 |
Trading Asset Securities | 97.7 | 69.46 | - | - |
Cash & Short-Term Investments | 405.79 | 517.69 | 121.35 | 96.22 |
Cash Growth | - | 326.63% | 26.12% | - |
Accounts Receivable | 4.45 | 6.7 | 9.86 | 38.97 |
Other Receivables | 22.06 | 28 | 17.24 | 23.55 |
Receivables | 26.51 | 34.7 | 27.1 | 62.51 |
Inventory | 7.47 | 8.76 | 7.7 | 7.33 |
Prepaid Expenses | 3.8 | 0.14 | 0 | 0.13 |
Other Current Assets | - | - | 3.25 | - |
Total Current Assets | 443.56 | 561.3 | 159.4 | 166.18 |
Property, Plant & Equipment | 681.6 | 632.55 | 483.73 | 435.36 |
Other Intangible Assets | 93.8 | 67.73 | 53.81 | 51.67 |
Long-Term Deferred Charges | - | 25.48 | 23.96 | 16.41 |
Other Long-Term Assets | 15.34 | 2.27 | 5.05 | 6.68 |
Total Assets | 1,234 | 1,289 | 725.96 | 676.3 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Accounts Payable | 6.4 | 5.87 | 3.5 | 0.62 |
Accrued Expenses | 68.16 | 62.28 | 29.01 | 29.26 |
Short-Term Debt | - | - | 11.27 | - |
Current Portion of Long-Term Debt | 266.15 | 307.78 | 151.97 | 133.75 |
Current Portion of Leases | 15.7 | 21.68 | 13.97 | 10.86 |
Current Income Taxes Payable | 1.59 | 1.67 | 1.3 | 1.59 |
Current Unearned Revenue | 10.91 | 10.23 | 18.81 | 7.14 |
Other Current Liabilities | 73.49 | 114.73 | 92.37 | 102.59 |
Total Current Liabilities | 442.4 | 524.23 | 322.2 | 285.81 |
Long-Term Debt | 554.46 | 292.19 | 222.16 | 145.78 |
Long-Term Leases | 22.15 | 24.93 | 28.36 | 30.64 |
Long-Term Unearned Revenue | 12.04 | 12.28 | 12.88 | 25.95 |
Total Liabilities | 1,031 | 853.62 | 585.59 | 488.18 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Common Stock | 167.6 | 167.6 | 6.6 | 6.36 |
Additional Paid-In Capital | - | 768.04 | 336.46 | 176.7 |
Retained Earnings | - | -567.08 | -211.36 | 0.04 |
Comprehensive Income & Other | 46.92 | 77.66 | 17.8 | 15.99 |
Total Common Equity | 214.52 | 446.22 | 149.5 | 199.09 |
Minority Interest | -11.28 | -10.52 | -9.13 | -10.98 |
Shareholders' Equity | 203.23 | 435.7 | 140.37 | 188.12 |
Total Liabilities & Equity | 1,234 | 1,289 | 725.96 | 676.3 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Total Debt | 858.46 | 646.57 | 427.72 | 321.03 |
Net Cash (Debt) | -452.68 | -128.88 | -306.37 | -224.81 |
Net Cash Growth | - | - | - | - |
Net Cash Per Share | -2.81 | -0.84 | -2.10 | -1.56 |
Filing Date Shares Outstanding | 167.6 | 167.6 | 6.6 | 144.56 |
Total Common Shares Outstanding | 167.6 | 167.6 | 6.6 | 144.56 |
Working Capital | 1.15 | 37.07 | -162.79 | -119.63 |
Book Value Per Share | 1.28 | 2.66 | 22.65 | 1.38 |
Tangible Book Value | 120.71 | 378.49 | 95.69 | 147.43 |
Tangible Book Value Per Share | 0.72 | 2.26 | 14.50 | 1.02 |
Buildings | - | 256.51 | 234.96 | 0.05 |
Machinery | - | 69.62 | 68.25 | 57.46 |
Construction In Progress | - | 232.71 | 81.01 | 255.45 |
Leasehold Improvements | - | 13.29 | 13.29 | 12.89 |